- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $40.39 – a decrease of 7.75% over the previous week. Crispr Therapeutics employs 407 staff and has a trailing 12-month revenue of around $202.8 million.
What's in this guide?
Our top picks for where to buy Crispr Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Crispr Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CRSP. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Crispr Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Crispr Therapeutics stock price (NASDAQ: CRSP)
Use our graph to track the performance of CRSP stocks over time.Crispr Therapeutics shares at a glance
Information last updated 2024-12-19.
| Latest market close | $40.39 |
|---|---|
| 52-week range | $40.61 - $91.10 |
| 50-day moving average | $48.65 |
| 200-day moving average | $54.43 |
| Wall St. target price | $81.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.79 |
Is it a good time to buy Crispr Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Crispr Therapeutics price performance over time
Historical closes compared with the close of $41.06 from 2024-12-18
| 1 week (2024-12-13) | -6.21% |
|---|---|
| 1 month (2024-11-21) | -11.30% |
| 3 months (2024-09-20) | -14.78% |
| 6 months (2024-06-21) | -26.99% |
| 1 year (2023-12-21) | -32.24% |
|---|---|
| 2 years (2022-12-21) | -9.60% |
| 3 years (2021-12-21) | 79.92 |
| 5 years (2019-12-20) | 68.06 |
Crispr Therapeutics financials
| Revenue TTM | $202.8 million |
|---|---|
| Gross profit TTM | $-570,697,000 |
| Return on assets TTM | -9.57% |
| Return on equity TTM | -13.07% |
| Profit margin | -118.13% |
| Book value | $22.73 |
| Market Capitalization | $3.5 billion |
TTM: trailing 12 months
Crispr Therapeutics share dividends
We're not expecting Crispr Therapeutics to pay a dividend over the next 12 months.
Have Crispr Therapeutics's shares ever split?
Crispr Therapeutics's shares were split on a 333333:100 basis on 18 July 2016 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your Crispr Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Crispr Therapeutics shares which in turn could have impacted Crispr Therapeutics's share price.
Crispr Therapeutics share price volatility
Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $40.61 up to $91.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.662. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crispr Therapeutics overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc. , Nkarta, Inc.
Frequently asked questions
What percentage of Crispr Therapeutics is owned by insiders or institutions?Currently 1.691% of Crispr Therapeutics shares are held by insiders and 74.723% by institutions. How many people work for Crispr Therapeutics?
Latest data suggests 407 work at Crispr Therapeutics. When does the fiscal year end for Crispr Therapeutics?
Crispr Therapeutics's fiscal year ends in December. Where is Crispr Therapeutics based?
Crispr Therapeutics's address is: Baarerstrasse 14, Zug, Switzerland, 6300 What is Crispr Therapeutics's ISIN number?
Crispr Therapeutics's international securities identification number is: CH0334081137 What is Crispr Therapeutics's CUSIP number?
Crispr Therapeutics's Committee on Uniform Securities Identification Procedures number is: H17182108
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question